The first human-sized questions
Completed phase 1 studies · Paper published April 22, 2026
What can small early trials tell us about tolerability and weight?
The next room has ordinary chairs. Subject One starts to sit in the volunteer’s place, notices the name on it is not his, and moves to the observer’s bench. Doctide hands him a blank question card: “What did they measure?” He writes SAFETY before touching the weight chart.
What changes here
Early human studies supported further testing; small, short studies cannot settle uncommon or long-term harms. [1]
Read the study details & dates
Two randomized, blinded, placebo-controlled trials
At one German centre, the single-exposure trial enrolled men with healthy weight or overweight; the repeated-exposure study included a later overweight/obesity cohort. EudraCT identifiers: 2021-001712-28 and 2022-001744-26. Petrelintide was injected subcutaneously; the single-exposure study also included an intravenous cohort. [1]
A weight signal, not an approval
Among 48 participants, observed mean weight reductions across three petrelintide cohorts were 4.8%, 8.6% and 8.3%, versus 1.7% with placebo. Weight was secondary to safety. These predominantly male, small cohorts were not a head-to-head comparison with another obesity medicine. [1]
What this does not establish
The publication date is not the date of first exposure. These completed studies do not establish long-term effectiveness or rule out rare adverse effects.
Original sources
Reviewed October 20, 2026: original phase 1 paper, including population, procedures and safety results. No dosing directions are provided.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story